Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by downregulating multidrug resistance

Blood

Volumn 94, Issue 7, 1999, Pages 2414-2423

  Smeets, Mariëlle E P ^a   Raymakers, Reinier A P ^a   Vierwinden, Gerty ^a   Pennings, Arie H M ^a   Wessels, Hans ^a   De Witte, Theo ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL SELECTION; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GROWTH STIMULATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0033214653     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.7.2414.417k01_2414_2423     Document Type: Article

References (44)

1. Campos L, Guyotat D, Archimbaud E, Calmard Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]. Blood 79:473, 1992
2. List AF: Multidrug resistance: Clinical relevance in acute leukemia. Oncology (Huntingt) 7:23, 1993
3. Samdani A, Vijapurkar U, Grimm MA, Spier CS, Grogan TM, Glinsmann Gibson BJ, List AF: Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). Leuk Res 20:175, 1996
4. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L: MDR1 gene expression and treatment outcome in acute myeloid leukemia [see comments]. J Natl Cancer Inst 83:708, 1991
5. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 85:186, 1995
6. Burger H, Nooter K, Zaman GJ, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8:990, 1994
7. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB: Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 8:2163, 1994
8. Frey T, Yue S, Haugland RP: Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance. Cytometry 20:218, 1995
9. Lautier D, Lahmy S, Canitrot Y, Vigo J, Viallet P, Salmon JM: Detection of human leukemia cells with multidrug-resistance phenotype using multilabeling with fluorescent dyes. Anticancer Res 13:1557, 1993
10. Neyfakh AA: Use of fluorescent dyes as molecular probes for the study of multidrug resistance. Exp Cell Res 174:168, 1988
11. Herweijer H, van den Engh G, Nooter K: A rapid and sensitive flow cytometric method for the detection of multidrug-resistant cells. Cytometry 10:463, 1989
12. Gheuens EE, van Bockstaele DR, van der Keur M, Tanke HJ, van Oosterom AT, De Bruijn EA: Flow cytometric double labeling technique for screening of multidrug resistance. Cytometry 12:636, 1991
13. Spangrude GJ, Johnson GR: Resting and activated subsets of mouse multipotent hematopoietic stem cells. Proc Natl Acad Sci USA 87:7433, 1990
14. Darzynkiewicz Z, Staiano Coico L, Melamed MR: Increased mitochondrial uptake of rhodamine 123 during lymphocyte stimulation. Proc Natl Acad Sci USA 78:2383, 1981
15. Myc A, DeAngelis P, Kimmel M, Melamed MR, Darzynkiewicz Z: Retention of the mitochondrial probe rhodamine 123 in normal lymphocytes and leukemic cells in relation to the cell cycle. Exp Cell Res 192:198, 1991
16. Minderman H, Linssen P, Wessels J, Haanen C: Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 13:1161, 1993
17. Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C: Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia 8:382, 1994
18. Tarasiuk J, Foucrier J, Garnier Suillerot A: Cell cycle dependent uptake and release of anthracycline by drug-resistant and drug-sensitive human leukaemic K562 cells. Biochem Pharmacol 45:1801, 1993
19. Ramachandran C, Mead D, Wellham LL, Sauerteig A, Krishan A: Expression of drug resistance-associated mdr-1, GST pi, and topoisomerase II genes during cell cycle traverse. Biochem Pharmacol 49:545, 1995
20. Smeets M, Raymakers R, Vierwinden G, Pennings A, van de Locht L, Wessels H, Boezeman J, de Witte T: A low but functionally significant MDR1 expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br J Haematol 96:346, 1997
21. Palutke M, Tabaczka PM, Kukuruga DL, Kantor NL: A method for measuring lymphocyte proliferation in mixed lymphocyte cultures using a nuclear proliferation antigen, Ki-67, and flow cytometry. Am J Clin Pathol 91:417, 1989
22. Brons PP, Haanen C, Boezeman JB, Muus P, Holdrinet RS, Pennings AH, Wessels HM, de Witte T: Proliferation patterns in acute myeloid leukemia: Leukemic clonogenic growth and in vivo cell cycle kinetics. Ann Hematol 66:225, 1993
23. van Erp PE, Brons PP, Boezeman JB, de Jongh GJ, Bauer FW: A rapid flow cytometric method for bivariate bromodeoxyuridine/DNA analysis using simultaneous proteolytic enzyme digestion and acid denaturation. Cytometry 9:627, 1988
24. Webb M, Raphael CL, Asbahr H, Erber WN, Meyer BF: The detection of rhodamine 123 efflux at low levels of drug resistance. Br J Haematol 93:650, 1996
25. van Bockstaele DR, Lan J, Snoeck HW, Korthout ML, De Bock RF, Peetermans ME: Aberrant Ki-67 expression in normal bone marrow revealed by multiparameter flow cytometric analysis. Cytometry 12:50, 1991
26. Raza A, Maheshwari Y, Preisler HD: Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood 69:1647, 1987
27. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S: GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro: A model for leukemia chemotherapy. Leuk Res 14:743, 1990
28. te Boekhorst PA, Lowenberg B, van Kapel J, Nooter K, Sonneveld P: Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 9:1025, 1995
29. Drach J, Zhao S, Drach D, Korbling M, Engel H, Andreeff M: Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma 16:419, 1995
30. Delwel R, Salem M, Pellens C, Dorssers L, Wagemaker G, Clark S, Lowenberg B: Growth regulation of human acute myeloid leukemia: Effects of five recombinant hematopoietic factors in a serum-free culture system. Blood 72:1944, 1988
31. Miyauchi J, Kelleher CA, Wong GG, Yang YC, Clark SC, Minkin S, Minden MD, McCulloch EA: The effects of combinations of the recombinant growth factors GM-CSF, G-CSF, IL-3, and CSF-1 on leukemic blast cells in suspension culture. Leukemia 2:382, 1988
32. Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD: Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1:584, 1987
33. Chabannon C, Mannoni P: Role of growth factors in the control of leukemic cell proliferation. Leuk Lymphoma 13:35, 1994
34. van der Lely N, de Witte T, Wessels J, Raymakers R, Muus P, Preijers F: In vitro response of blasts to IL-3, GM-CSF, and G-CSF is different for individual AML patients: Factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Ann Hematol 68:225, 1994
35. Boezeman J, Raymakers R, Vierwinden G, Linssen P: Automatic analysis of growth onset, growth rate and colony size of individual bone marrow progenitors. Cytometry 28:305, 1997
36. Pirker R, Zochbauer S, Kupper H, Lassmann A, Gsur A, Frass M, Krajnik G, Knobl P, Lechner K: Dexverapamil as resistance modifier in acute myeloid leukaemia. J Cancer Res Clin Oncol 121:21, 1995
37. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia [see comments]. J Clin Oncol 11:1652, 1993
38. Nussler V, Pelka Fleischer R, Zwierzina H, Nerl C, Beckert B, Gullis E, Gieseler F, Bock S, Bartl R, Petrides PE, et al: Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes - first experience with their reversal. Ann Hematol 69:S25, 1994
39. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy [see comments]. J Clin Oncol 7:415, 1989
40. Raderer M, Scheithauer W: Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72:3553, 1993
41. Tafuri A, Lemoli RM, Chen R, Gulati SC, Clarkson BD, Andreeff M: Combination of hematopoietic growth factors containing IL-3 induce acute myeloid leukemia cell sensitization to cycle specific and cycle non-specific drugs. Leukemia 8:749, 1994
42. Lowenberg B, de Greef GE, Wielenga JJ: Granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of hematological malignancies. Anticancer Drugs 4:17, 1993
43. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700, 1991
44. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrozek K, Swann VL, Minderman H, Block AW, Pixley LA, Christiansen NP, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD: Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. Blood 87:1484, 1996